Shortly after Cameron Harding’s one-month check-up, his mother, Alison, saw that her newborn seemed to stop moving. She’d unwrap him from a swaddle and his arms would flop to one side. He wouldn’t kick his legs or turn his head.
The diagnosis: spinal muscular atrophy.
Cameron’s case was severe enough he’d probably never even have a birthday.
But when he was seven weeks old, Cameron’s parents enrolled him in a clinical trial for an experimental drug. In videos shot two months later, he could move his head and reach for a toy. No child with his condition had ever made such a recovery before.
The drug Cameron received, Spinraza, was approved in the U.S. just before Christmas and may become the first blockbuster in a novel category of drugs called RNA therapeutics…
Share this article
What drugs like Spinraza seek to do instead is use RNA to block, modify, or add to, the existing RNA messages in a cell.
“The dirty secret of RNA therapies is that most people are working on stuff where there is competition and there are other molecules,” [Rachel Meyers, previously a senior executive at Alnylam] says. “It’s those ones that don’t have a good alternative where you say, ‘Oh my gosh, we can really change the world, or someone’s life, with this.’
The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: How a Boy’s Lazarus-like Revival Points to a New Generation of Drug
For more background on the Genetic Literacy Project, read GLP on Wikipedia.
